
    
      A phase II, open-label, non-randomized, pilot study assessing the safety, toxicity, and
      progression free survival of advanced stage ovarian carcinoma patients who underwent
      treatment with paclitaxel, carboplatin and metformin. An estimated 30 patients will be
      required for this study.
    
  